Wei Liu1,2, Yin Ting Cheung3, Heather M Conklin4, Lisa M Jacola4, DeoKumar Srivastava1, Vikki G Nolan2, Hongmei Zhang2, James G Gurney2, I-Chan Huang3, Leslie L Robison3, Ching-Hon Pui5, Melissa M Hudson3,5, Kevin R Krull6,7. 1. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA. 2. School of Public Health, University of Memphis, Memphis, TN, USA. 3. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 735, Memphis, TN, 38105, USA. 4. Department of Psychology, St. Jude Children's Research Hospital, Memphis, TN, USA. 5. Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 6. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 735, Memphis, TN, 38105, USA. kevin.krull@stjude.org. 7. Department of Psychology, St. Jude Children's Research Hospital, Memphis, TN, USA. kevin.krull@stjude.org.
Abstract
PURPOSE: The purpose of this study was to determine the evolution of neurocognitive problems from therapy completion to long-term follow-up in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. METHODS: We evaluated whether attention problems observed at therapy completion evolve into long-term executive dysfunction in 158 survivors treated on a single institution protocol. Treatment data (high-dose intravenous methotrexate exposure [serum concentration] and triple intrathecal chemotherapy injections) were collected. Parent report of behavior and direct cognitive testing of survivors was conducted at end of therapy, and survivors completed neurocognitive testing when > 5 years post-diagnosis. RESULTS: At the end of chemotherapy, survivors (52% female; mean age 9.2 years) demonstrated higher frequency of impairment in sustained attention (38%) and parent-reported inattention (20%) compared to population expectations (10%). At long-term follow-up, survivors (mean age 13.7 years; 7.6 years post-diagnosis) demonstrated higher impairment in executive function (flexibility 24%, fluency 21%), sustained attention (15%), and processing speed (15%). Sustained attention improved from end of therapy to long-term follow-up (p < 0.001). Higher methotrexate AUC and greater number of intrathecal injections were associated with attention problems (p = 0.009, p = 0.002, respectively) at the end of chemotherapy and executive function (p < 0.001, p = 0.02, respectively) problems at long-term follow-up. Attention problems at the end of therapy were not associated with executive function problems at long-term follow-up (p's > 0.05). The direct effect of chemotherapy exposure predicted outcomes at both time points. CONCLUSIONS AND IMPLICATIONS FOR CANCER SURVIVORS: Survivors should be monitored for neurocognitive problems well into long-term survivorship, regardless of whether they show attention problems at the end of therapy. Treatment exposures are the best predictor of long-term complications.
PURPOSE: The purpose of this study was to determine the evolution of neurocognitive problems from therapy completion to long-term follow-up in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. METHODS: We evaluated whether attention problems observed at therapy completion evolve into long-term executive dysfunction in 158 survivors treated on a single institution protocol. Treatment data (high-dose intravenous methotrexate exposure [serum concentration] and triple intrathecal chemotherapy injections) were collected. Parent report of behavior and direct cognitive testing of survivors was conducted at end of therapy, and survivors completed neurocognitive testing when > 5 years post-diagnosis. RESULTS: At the end of chemotherapy, survivors (52% female; mean age 9.2 years) demonstrated higher frequency of impairment in sustained attention (38%) and parent-reported inattention (20%) compared to population expectations (10%). At long-term follow-up, survivors (mean age 13.7 years; 7.6 years post-diagnosis) demonstrated higher impairment in executive function (flexibility 24%, fluency 21%), sustained attention (15%), and processing speed (15%). Sustained attention improved from end of therapy to long-term follow-up (p < 0.001). Higher methotrexate AUC and greater number of intrathecal injections were associated with attention problems (p = 0.009, p = 0.002, respectively) at the end of chemotherapy and executive function (p < 0.001, p = 0.02, respectively) problems at long-term follow-up. Attention problems at the end of therapy were not associated with executive function problems at long-term follow-up (p's > 0.05). The direct effect of chemotherapy exposure predicted outcomes at both time points. CONCLUSIONS AND IMPLICATIONS FOR CANCER SURVIVORS: Survivors should be monitored for neurocognitive problems well into long-term survivorship, regardless of whether they show attention problems at the end of therapy. Treatment exposures are the best predictor of long-term complications.
Authors: Adriani Kanellopoulos; Stein Andersson; Bernward Zeller; Christian K Tamnes; Anders M Fjell; Kristine B Walhovd; Lars T Westlye; Sophie D Fosså; Ellen Ruud Journal: Pediatr Blood Cancer Date: 2015-08-27 Impact factor: 3.167
Authors: Deepa Bhojwani; Noah D Sabin; Deqing Pei; Jun J Yang; Raja B Khan; John C Panetta; Kevin R Krull; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Scott C Howard; Raul C Ribeiro; Cheng Cheng; Wilburn E Reddick; Sima Jeha; John T Sandlund; William E Evans; Ching-Hon Pui; Mary V Relling Journal: J Clin Oncol Date: 2014-02-18 Impact factor: 44.544
Authors: Kevin R Krull; Tara M Brinkman; Chenghong Li; Gregory T Armstrong; Kirsten K Ness; Deo Kumar Srivastava; James G Gurney; Cara Kimberg; Matthew J Krasin; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2013-11-04 Impact factor: 44.544
Authors: Kevin R Krull; Yin Ting Cheung; Wei Liu; Slim Fellah; Wilburn E Reddick; Tara M Brinkman; Cara Kimberg; Robert Ogg; Deokumar Srivastava; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544
Authors: Stephanie B Dixon; Yan Chen; Yutaka Yasui; Ching-Hon Pui; Stephen P Hunger; Lewis B Silverman; Kirsten K Ness; Daniel M Green; Rebecca M Howell; Wendy M Leisenring; Nina S Kadan-Lottick; Kevin R Krull; Kevin C Oeffinger; Joseph P Neglia; Ann C Mertens; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Paul C Nathan Journal: J Clin Oncol Date: 2020-07-24 Impact factor: 44.544
Authors: Priscilla Vasquez; Johanna Escalante; Kimberly P Raghubar; Lisa S Kahalley; Olga A Taylor; Ida Ki Moore; Marilyn J Hockenberry; Michael E Scheurer; Austin L Brown Journal: Pediatr Blood Cancer Date: 2021-12-10 Impact factor: 3.167
Authors: Meghan Phelan; Susan S Hayashi; Kara Sauerburger; Jennifer Henry; Ningying Wu; Robert J Hayashi Journal: Pediatr Blood Cancer Date: 2021-12-02 Impact factor: 3.167
Authors: Ellen van der Plas; T Leigh Spencer Noakes; Darci T Butcher; Rosanna Weksberg; Laura Galin-Corini; Elizabeth A Wanstall; Patrick Te; Laura Hopf; Sharon Guger; Johann Hitzler; Russell J Schachar; Shinya Ito; Brian J Nieman Journal: Pediatr Res Date: 2020-11-17 Impact factor: 3.953
Authors: AnnaLynn M Williams; Yin Ting Cheung; Geehong Hyun; Wei Liu; Kirsten K Ness; Matthew J Ehrhardt; Daniel A Mulrooney; Nickhill Bhakta; Pia Banerjee; Tara M Brinkman; Daniel M Green; Wassim Chemaitilly; I-Chan Huang; Deokumar Srivastava; Melissa M Hudson; Leslie L Robison; Kevin R Krull Journal: Ann Neurol Date: 2020-12-31 Impact factor: 10.422
Authors: Ellen van der Plas; Weiyu Qiu; Brian J Nieman; Yutaka Yasui; Qi Liu; Stephanie B Dixon; Nina S Kadan-Lottick; Christopher B Weldon; Brent R Weil; Lisa M Jacola; Todd M Gibson; Wendy Leisenring; Kevin Oeffinger; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Natl Cancer Inst Date: 2021-05-04 Impact factor: 13.506
Authors: AnnaLynn M Williams; Kevin R Krull; Carrie R Howell; Pia Banerjee; Tara M Brinkman; Sue C Kaste; Robyn E Partin; Deokumar Srivastava; Yutaka Yasui; Gregory T Armstrong; Leslie L Robison; Melissa M Hudson; Kirsten K Ness Journal: J Clin Oncol Date: 2021-07-20 Impact factor: 44.544
Authors: Ellen van der Plas; T Leigh Spencer Noakes; Darci T Butcher; Rosanna Weksberg; Laura Galin-Corini; Elizabeth A Wanstall; Patrick Te; Laura Hopf; Sharon Guger; Brenda J Spiegler; Johann Hitzler; Russell J Schachar; Shinya Ito; Brian J Nieman Journal: Neuroimage Clin Date: 2020-09-15 Impact factor: 4.881